Document is current
Any future updates will be listed below
-
Authors
Billings, Liana K.
Asong, Marisse
Bøg, Martin
Clancy, Simon
Kruse, Christian
de Laguiche, Elisabeth
Maddaloni, Ernesto
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04760626 at ClinicalTrials.govDocuments that mention this clinical trial
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
https://doi.org/10.2337/dc20-2878
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
AUGMENTed Real-World Data Enhances Comparative Efficacy Between Once-Weekly Insulin Icodec with Dosing Guide App Versus Once-Daily Insulin Glargine U300 in Insulin-Naive Type 2 Diabetes
https://doi.org/10.1007/s13300-024-01679-3
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 25 October 2024
Accepted: 27 November 2024
First Online: 19 December 2024
Declarations
:
: Liana K. Billings has received research support and consultant fees from, or has served on advisory panels for, Bayer, Dexcom, Eli Lilly, Endogenex, Novo Nordisk, Pfizer, and Sanofi. Ernesto Maddaloni has received research support and consultant fees from, or has served on advisory panels for, Abbott, Eli Lilly, Merck Serono, Merck Sharp & Dohme, MTD, Novo Nordisk, and Pikdare. Marisse Asong, Martin Bøg, Simon Clancy, Christian Kruse, and Elisabeth de Laguiche are employees of Novo Nordisk A/S and hold stock options.
: The trial was conducted in compliance with the principles of the Declaration of Helsinki and in accordance with International Conference for Harmonization Good Clinical Practice guidelines. Relevant documents, including the protocol and consent forms, were approved by institutional review boards or independent ethics committees. All participants provided written informed consent for participation and publication of data before trial entry and could withdraw their consent at any time.
